摘要
目的探讨新辅助化疗在局部晚期非小细胞肺癌(NSCLC)手术中的临床效果。方法 110例Ⅲ期NSCLC患者随机分为观察组和对照组各55例,观察组患者在接受2个周期的全身化疗后手术,对照组确诊后直接手术。比较两组患者的手术情况和术后生存率。结果观察组的手术切除率为89.1%,显著高于对照组的74.5%(P<0.05);观察组的术中出血量和手术时间显著低于对照组(P<0.05);观察组术后1年、2年、3年生存率分别为85.5%、67.3%、56.4%,对照组分别为69.1%、54.5%、47.3%,两组间比较有统计学差异(P<0.05)。结论术前新辅助化疗可以提高NSCLC的手术切除率,增加患者的术后生存率。
Objective To explore the clinical efficacy of neo-adjuvant chemotherapy in the surgery of locally advanced non-small cell lung cancer（NSCLC）.Methods 110 NSCLC patients at stage Ⅲ were randomly and evenly divided into the test group and the control group.The test group was given neo-adjuvant chemotherapy before surgical treatment,and the control group was given surgical treatment directly.The surgical situations and postoperative survivals were compared after the treatment.Results The resection rate of the test group was 89.1%,which was significantly higher than that of the control group（74.5%）（P〈0.05）.Blood loss and operation duration were significantly lower in the test group than in the control group（P〈0.05）.The survival rates of 1 year,2 years and 3 years after the surgery were 85.5%,67.3% and 56.4% in the test group and 69.1%,54.5% and 47.3% in the control group respectively.There were significant differences between the two groups（P〈0.05）.Conclusion Neo-adjuvant chemotherapy can significantly increase resection rate and long term survival rate,which is worthy of widely clinical application.
出处
《临床肺科杂志》
2013年第7期1285-1286,共2页
Journal of Clinical Pulmonary Medicine
关键词
非小细胞肺癌
新辅助化疗
手术治疗
吉西他滨
non-small cell lung cancer
neo-adjuvant chemotherapy
surgical treatment
gemcitabine
